{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:46:00Z","timestamp":1774367160811,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Edmond and Benjamin de Rothschild Foundation"},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["338\/19"],"award-info":[{"award-number":["338\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Argonauts Biotech ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26000-5","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T15:14:55Z","timestamp":1763824495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Hagit","family":"Masika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Cherniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Britan-Rosich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonatan","family":"Oster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Grupel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Nama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batel","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Planer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Strahilevitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orna","family":"Mor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveliy","family":"Kirillov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Dessau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Fahoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einav","family":"Cohen-Kfir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matan","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuven","family":"Wiener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reaan","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Rouvinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hila","family":"Elinav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"26000_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (2023)."},{"key":"26000_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/CEOR.S338225","volume":"14","author":"F Richards","year":"2022","unstructured":"Richards, F. et al. Economic burden of COVID-19: A systematic review. Clinicoecon Outcomes Res. 14, 293\u2013307. https:\/\/doi.org\/10.2147\/CEOR.S338225 (2022).","journal-title":"Clinicoecon Outcomes Res."},{"key":"26000_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet. Infect. Dis. 22, 1293\u20131302. https:\/\/doi.org\/10.1016\/S1473-3099(22)00320-6 (2022).","journal-title":"Lancet. Infect. Dis."},{"key":"26000_CR4","unstructured":"US Food and Drug administration. Anti-SARS-CoV-2 Monoclonal Antibodies, https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/ (2024)."},{"key":"26000_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273. https:\/\/doi.org\/10.1038\/s41586-020-2012-7 (2020).","journal-title":"Nature"},{"key":"26000_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8 (2020).","journal-title":"Lancet"},{"key":"26000_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.it.2020.04.008","volume":"41","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses: (trends in immunology 41, 355\u2013359; 2020). Trends Immunol 41, 545. https:\/\/doi.org\/10.1016\/j.it.2020.04.008 (2020).","journal-title":"Trends Immunol"},{"key":"26000_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.05.047","volume":"181","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1436\u20131441. https:\/\/doi.org\/10.1016\/j.cell.2020.05.047 (2020).","journal-title":"Cell"},{"key":"26000_CR9","doi-asserted-by":"publisher","unstructured":"Hicks, J. et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv, https:\/\/doi.org\/10.1101\/2020.06.22.20137695 (2020).","DOI":"10.1101\/2020.06.22.20137695"},{"key":"26000_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70071","author":"B Alosaimii","year":"2025","unstructured":"Alosaimii, B. et al. 10 Year long-lived cellular and humoral MERS-CoV immunity cross-recognizing the wild-type and variants of SARS-CoV-2: A potential one-way MERS-CoV cross-protection toward a pan-coronavirus vaccine. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.70071 (2025).","journal-title":"J. Med. Virol."},{"key":"26000_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/vaccines11030552","volume":"11","author":"JM AlKhalifah","year":"2023","unstructured":"AlKhalifah, J. M. et al. Impact of MERS-CoV and SARS-CoV-2 viral infection on immunoglobulin-IgG cross-reactivity. Vaccines (Basel) 11, 552. https:\/\/doi.org\/10.3390\/vaccines11030552 (2023).","journal-title":"Vaccines (Basel)"},{"key":"26000_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.19222","volume":"6","author":"HT Zedan","year":"2023","unstructured":"Zedan, H. T. et al. Assessment of broadly reactive responses in patients With MERS-CoV infection and SARS-CoV-2 vaccination. JAMA Netw Open 6, e2319222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.19222 (2023).","journal-title":"JAMA Netw Open"},{"key":"26000_CR13","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2542-5196(19)30243-8","volume":"3","author":"SA El-Kafrawy","year":"2019","unstructured":"El-Kafrawy, S. A. et al. Enzootic patterns of Middle East respiratory syndrome coronavirus in imported African and local Arabian dromedary camels: a prospective genomic study. Lancet. Planet. Health 3, e521\u2013e528. https:\/\/doi.org\/10.1016\/S2542-5196(19)30243-8 (2019).","journal-title":"Lancet. Planet. Health"},{"key":"26000_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.onehlt.2018.05.002","volume":"5","author":"D David","year":"2018","unstructured":"David, D. et al. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. One Health 5, 65\u201368. https:\/\/doi.org\/10.1016\/j.onehlt.2018.05.002 (2018).","journal-title":"One Health"},{"key":"26000_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0167-4838(99)00030-8","volume":"1431","author":"RH van der Linden","year":"1999","unstructured":"van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1431, 37\u201346. https:\/\/doi.org\/10.1016\/s0167-4838(99)00030-8 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"26000_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fimmu.2017.00653","volume":"8","author":"CFC Fernandes","year":"2017","unstructured":"Fernandes, C. F. C. et al. Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases. Front Immunol. 8, 653. https:\/\/doi.org\/10.3389\/fimmu.2017.00653 (2017).","journal-title":"Front Immunol."},{"key":"26000_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11033-021-06819-7","volume":"49","author":"A Zebardast","year":"2022","unstructured":"Zebardast, A., Hosseini, P., Hasanzadeh, A. & Latifi, T. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. Mol. Biol. Rep. 49, 647\u2013656. https:\/\/doi.org\/10.1007\/s11033-021-06819-7 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"26000_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/nu3040442","volume":"3","author":"WL Hurley","year":"2011","unstructured":"Hurley, W. L. & Theil, P. K. Perspectives on immunoglobulins in colostrum and milk. Nutrients 3, 442\u2013474. https:\/\/doi.org\/10.3390\/nu3040442 (2011).","journal-title":"Nutrients"},{"key":"26000_CR19","doi-asserted-by":"publisher","first-page":"14165","DOI":"10.1038\/s41598-023-41399-5","volume":"13","author":"A Rouvinski","year":"2023","unstructured":"Rouvinski, A. et al. Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine. Sci. Rep. 13, 14165. https:\/\/doi.org\/10.1038\/s41598-023-41399-5 (2023).","journal-title":"Sci. Rep."},{"key":"26000_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933347","volume":"13","author":"M Stolovich-Rain","year":"2022","unstructured":"Stolovich-Rain, M. et al. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA. Front Immunol. 13, 933347. https:\/\/doi.org\/10.3389\/fimmu.2022.933347 (2022).","journal-title":"Front Immunol."},{"key":"26000_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145785","volume":"6","author":"L Chouchane","year":"2021","unstructured":"Chouchane, L. et al. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2. JCI Insight 6, e145785. https:\/\/doi.org\/10.1172\/jci.insight.145785 (2021).","journal-title":"JCI Insight"},{"key":"26000_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220. https:\/\/doi.org\/10.1038\/s41586-020-2180-5 (2020).","journal-title":"Nature"},{"key":"26000_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448. https:\/\/doi.org\/10.1126\/science.abb2762 (2020).","journal-title":"Science"},{"key":"26000_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/nure.12089","volume":"72","author":"M Rathe","year":"2014","unstructured":"Rathe, M., Muller, K., Sangild, P. T. & Husby, S. Clinical applications of bovine colostrum therapy: a systematic review. Nutr Rev 72, 237\u2013254. https:\/\/doi.org\/10.1111\/nure.12089 (2014).","journal-title":"Nutr Rev"},{"key":"26000_CR25","doi-asserted-by":"crossref","unstructured":"Marlina P, K. H. Encyclopedia of Dairy Sciences. 591\u2013597 (2011).","DOI":"10.1016\/B978-0-12-374407-4.00322-8"},{"key":"26000_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268806","volume":"17","author":"K Kangro","year":"2022","unstructured":"Kangro, K. et al. Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. PLoS ONE 17, e0268806. https:\/\/doi.org\/10.1371\/journal.pone.0268806 (2022).","journal-title":"PLoS ONE"},{"key":"26000_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.17221\/10\/2017-CJFS","volume":"35","author":"V Skalka","year":"2019","unstructured":"Skalka, V., Shakhno, N., Ecer, J. & Curda, L. Separation of immunoglobulins from colostrum using methods based on salting-out techniques. Czech. J. Food Sci. 35, 259\u2013266. https:\/\/doi.org\/10.17221\/10\/2017-CJFS (2019).","journal-title":"Czech. J. Food Sci."},{"key":"26000_CR28","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e250","volume":"38","author":"Y Jo","year":"2023","unstructured":"Jo, Y., Kim, S. B. & Jung, J. A model-based cost-effectiveness analysis of long-acting monoclonal antibody (tixagevimab and cilgavimab: evusheld) preventive treatment for high-risk populations against SARS-CoV-2 in Korea. J Korean Med Sci 38, e250. https:\/\/doi.org\/10.3346\/jkms.2023.38.e250 (2023).","journal-title":"J Korean Med Sci"},{"key":"26000_CR29","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/v14102278","volume":"14","author":"D Totschnig","year":"2022","unstructured":"Totschnig, D. et al. SARS-CoV-2 pre-exposure prophylaxis with sotrovimab and tixagevimab\/cilgavimab in immunocompromised patients-a single-center experience. Viruses 14, 2278. https:\/\/doi.org\/10.3390\/v14102278 (2022).","journal-title":"Viruses"},{"key":"26000_CR30","doi-asserted-by":"publisher","first-page":"2284297","DOI":"10.1080\/22221751.2023.2284297","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China. Emerg. Microbes. Infect. 13, 2284297. https:\/\/doi.org\/10.1080\/22221751.2023.2284297 (2023).","journal-title":"Emerg. Microbes. Infect."},{"key":"26000_CR31","doi-asserted-by":"publisher","first-page":"15648","DOI":"10.1038\/s41598-023-42539-7","volume":"13","author":"T Imsuwansri","year":"2023","unstructured":"Imsuwansri, T. et al. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers. Sci Rep 13, 15648. https:\/\/doi.org\/10.1038\/s41598-023-42539-7 (2023).","journal-title":"Sci Rep"},{"key":"26000_CR32","doi-asserted-by":"publisher","first-page":"110326","DOI":"10.1016\/j.isci.2024.110326","volume":"27","author":"K Gildemann","year":"2024","unstructured":"Gildemann, K. et al. Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets. iScience 27, 110326. https:\/\/doi.org\/10.1016\/j.isci.2024.110326 (2024).","journal-title":"iScience"},{"key":"26000_CR33","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1093\/cid\/ciac448","volume":"76","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: a small-scale clinical trial. Clin. Infect. Dis. 76, e336\u2013e341. https:\/\/doi.org\/10.1093\/cid\/ciac448 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"26000_CR34","doi-asserted-by":"publisher","first-page":"2212806","DOI":"10.1080\/22221751.2023.2212806","volume":"12","author":"R Song","year":"2023","unstructured":"Song, R. et al. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study. Emerg. Microbes. Infect. 12, 2212806. https:\/\/doi.org\/10.1080\/22221751.2023.2212806 (2023).","journal-title":"Emerg. Microbes. Infect."},{"key":"26000_CR35","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1016\/j.cell.2024.09.043","volume":"187","author":"Y Xiang","year":"2024","unstructured":"Xiang, Y. et al. Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy. Cell 187, 6966\u20136980. https:\/\/doi.org\/10.1016\/j.cell.2024.09.043 (2024).","journal-title":"Cell"},{"key":"26000_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1541269","author":"S Sun","year":"2025","unstructured":"Sun, S. et al. Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1541269 (2025).","journal-title":"Front Immunol."},{"issue":"6","key":"26000_CR37","doi-asserted-by":"publisher","first-page":"e2319222","DOI":"10.1001\/jamanetworkopen.2023.19222","volume":"6","author":"HT Zedan","year":"2023","unstructured":"Zedan, H. T. et al. Assessment of broadly reactive responses in patients with MERS-CoV infection and SARS-CoV-2 vaccination. AMA Netw. Open 6(6), e2319222\u2013e2319222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.19222 (2023).","journal-title":"AMA Netw. Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26000-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:59:06Z","timestamp":1764086346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26000-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26000"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26000-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42007"}}